Profil
Naoya Sato is currently Director & Administration Manager at AnGes, Inc. since 2025.
Formerly, Dr. Sato was Director-Business Development at Tanabe Pharma Corp.
from 2019 to 2025 and Director at MP Healthcare Venture Management, Inc. from 2015 to 2019.
Education includes undergraduate, graduate, and doctorate degrees from Osaka University, all conferred in 1993.
Postes actifs de Naoya Sato
| Sociétés | Poste | Début |
|---|---|---|
| ANGES, INC. | Directeur Administratif | 01/08/2024 |
Anciens postes connus de Naoya Sato
| Sociétés | Poste | Fin |
|---|---|---|
| MITSUBISHI TANABE PHARMA CORPORATION | Directeur/Membre du Conseil | 23/06/2025 |
MP Healthcare Venture Management, Inc.
MP Healthcare Venture Management, Inc. Investment ManagersFinance MP Healthcare Venture invests in companies located in the North America and Europe. The firm focuses on sectors such as biotechnology, biopharmaceuticals, therapeutics and diagnostics. It participates in seed and early stage capital transactions. | Directeur/Membre du Conseil | - |
Formation de Naoya Sato
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Mitsubishi Tanabe Pharma Corp.
Mitsubishi Tanabe Pharma Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products | Health Technology |
AnGes, Inc.
AnGes, Inc. Pharmaceuticals: GenericHealth Technology Manufactures gene pharmaceutical medicines | Health Technology |
Osaka University
Osaka University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MP Healthcare Venture Management, Inc.
MP Healthcare Venture Management, Inc. Investment ManagersFinance MP Healthcare Venture invests in companies located in the North America and Europe. The firm focuses on sectors such as biotechnology, biopharmaceuticals, therapeutics and diagnostics. It participates in seed and early stage capital transactions. | Finance |
















